AstraZeneca says U.S. FDA approves rare kidney disease drug
The key positive catalyst is the news that AstraZeneca has received approval from the U.S. FDA for its rare kidney disease treatment.
The current price is situated just below the 20-day resistance level ($169.81), and entry is being considered under the judgment that it is necessary to verify whether the price undergoes a mild consolidation above the support level ($154.00) on increased trading volume.
If the upward trend is driven by a combination of FDA approval catalysts and earnings release expectations, set the profit-taking target at the resistance level of $169.81. Conversely, manage risk by cutting losses if the price breaks below the support level of $154.00.
RSI(14) 61.4, moving averages in non-bullish alignment, trading volume 1.65x the 20-day average, 7-day volatility +6.0%
Based on past history of +3.5% on Oct 21, 2026, +2.2% on Oct 20, 2026, +6.6% on Oct 12, 2026, +3.5% on Oct 5, 2026, and -1.7% on Sep 29, 2026, this stock can be approached by recognizing a pattern of exhibiting consistent upward momentum whenever individual positive catalysts occur.
It recorded a predicted return of 2.5%, but actually achieved a return of 10.8%, resulting in an OVERHIT rating. Immediately following the news of the FDA's approval of a rare kidney disease treatment, the subsequent Q3 earnings release (Non-GAAP EPS of $2.79, beating revenue of $16.21B, and strong sales of cancer treatments) and the reaction during the earnings conference call—"beats Q3 2026 estimates, shares rise 7%"—combined to create strong upward momentum that surpassed expectations for a mild correction near the initial resistance line ($169.81). Although the RSI of 61.4 at the time of entry and trading volume 1.65 times the 20-day average already hinted at an influx of buying pressure, the failure to fully anticipate the magnitude of the actual outcome, which reflected additional earnings surprise momentum, is a point to be reviewed.
This trade confirmed that when positive catalysts and earnings announcements overlap, a stronger-than-expected upward surge can occur. For future entries, in addition to setting conservative profit-taking targets near resistance levels, we will adjust our execution plan to more flexibly capture the opportunity for excess gains through a scaled profit-taking strategy during periods when major positive news and earnings release dates closely overlap.